Core Insights - Glucotrack, Inc. has entered into a collaboration with OneTwo Analytics AB to enhance the clinical study data analysis of its Continuous Blood Glucose Monitor (CBGM) using AI and machine learning technologies [1][3] - The CBGM is designed to provide real-time blood glucose readings directly from blood, offering a more accurate and less intrusive monitoring solution compared to traditional continuous glucose monitors [2][6] - The partnership aims to create a comprehensive ecosystem for diabetes management, integrating blood glucose insights, risk stratification data, and patient engagement tools [3][7] Company Overview - Glucotrack, Inc. focuses on developing innovative technologies for diabetes management, specifically a long-term implantable continuous blood glucose monitoring system [5][6] - OneTwo Analytics specializes in AI-driven healthcare solutions, particularly in diabetes data analysis and technology stack development [7][8] Product Features - The CBGM is a long-term implantable device with a sensor longevity of three years, requiring minimal calibration and having no external components [2][6] - This device aims to provide continuous and accurate blood glucose monitoring, enhancing the convenience for users [2][6] Strategic Goals - The collaboration with OneTwo Analytics is expected to leverage their analytics expertise to quantify the long-term benefits of the CBGM technology [3] - Both companies aim to revolutionize diabetes management by delivering an end-to-end solution for healthcare providers and patients [3][7]
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor